Fig. 7
Inhibition of ABCB1 with verapamil promotes significant cytotoxicity in MDAR cells. (A) Evaluation of Dox efflux under 24 h treatment with dox (1.6 µM) and concomitant treatment with the ABCB1 inhibitor (Verapamil) (10 µM). (B) MTT viability assay under the same conditions. Molecular docking assay of ABCB1 (PDB: 7A69) under dox and verapamil interaction (C), an approach to the interaction region of the ligands dox (yellow) and verapamil (magenta) is shown (D), and prediction of ABCB1 residues determinants of verapamil interaction obtained by the MOE program. Results showed three biological replicates’ mean and standard deviation (n = 3, X ± S.D.). Data were statistically analyzed using one-way ANOVA and Newman–Keuls’s multiple comparison test, * represents a p value < 0.05** represents a p value < 0.01.
